Forma Therapeutics, Inc.

Foghorn Therapeutics Inc.

Valo Health, Inc.

Valo Early Discovery, Inc.

Shawn E R Schiller

Kenneth W Bair

Hongbin Li

Matthew W Martin

Torsten Herbertz

David S Millan

Steven Gregory Mischke

George P Luke

Mark Joseph Tebbe

David R Lancia, Jr

Adam Charles Talbot

Katherine J Kayser-Bricker

Goss S Kauffman

Anna M Ericsson

Angela V West

Bradford Graves

Jennifer R Downing

Wei Lu

James Loch

Justin Andrew Caravella

David James Richard

David Joseph Guerin

Tatiana Shelekhin

Pui Yee Ng

Zhongguo Wang

Stephanos Ioannidis

Neville J Anthony

Rishi G Vaswani

David Simon Millan

Solymar Negretti

Kevin J Wilson

Robert Wenslow

Jun Huang

David S Huang

Stephen Hubbs

Yawei Shi

Melek Nihan Ucisik

Richard Caldwell

Neville John Anthony

David R Lancia Jr

Goss Stryker Kauffman

Mark J Tebbe

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

Compounds and uses thereof

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Inhibiting CREB binding protein (CBP)

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

Inhibiting cyclic AMP-responsive element-binding protein (CREB)

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments. The present disclosure provides compounds of Formula (I).

Inhibiting deubiquitinase USP25 and USP28

The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.

Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R, R, R, R, R, R, R, X, and n are described herein. 

Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors

The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone: 

Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R, R, R, and Rare as described herein.

Tetrahydroquinoline compositions as BET bromodomain inhibitors

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R, R, Rand Rare defined herein.

Benzopiperazine compositions as BET bromodomain inhibitors

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below: 

Compounds and compositions for inhibition of FASN

Growing community of inventors

Haverhill, MA, United States of America

Shawn E R Schiller